What NILO Therapeutics does

NILO Therapeutics is a New York City-based, preclinical-stage biotechnology company developing a new class of medicines that modulate systemic inflammation by targeting master regulator brain-body circuits. Its core asset is the Neural Circuit Immunomodulation Platform, a therapeutic approach grounded in academic research (including referenced Nature body-brain axis work) that aims to centrally control immune responses and restore immune homeostasis, with the stated potential to treat a wide spectrum of autoimmune and inflammatory diseases. The platform differentiates from existing immunomodulatory therapies by acting centrally on neural circuitry rather than on peripheral immune targets, addressing an unmet need where current treatments often have significant side effects or incomplete efficacy.

The company was founded in 2025 and launched publicly in October 2025 alongside a $101 million Series A financing — one of the largest Series A rounds in biotech history — led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Bill & Melinda Gates Foundation and Alexandria Venture Investments. Proceeds are allocated to establishing research laboratories in New York City, expanding the R&D team, and advancing preclinical programs. Nilo is led by CEO Kim Seth and CSO Laurens Kruidenier.

As a pre-revenue biotech, Nilo's future revenue model contemplates eventual drug commercialization through standard pharmaceutical distribution (one-time license economics in its current characterization), targeting two patient segments: autoimmune disease patients and inflammatory disease patients beyond core autoimmune indications. No commercial products, pricing, or licensing deals have been disclosed.

Name

NILO Therapeutics

Legal name

Nilo Therapeutics

Website

https://nilotx.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

NILO Therapeutics is a preclinical-stage New York City biotech developing a Neural Circuit Immunomodulation Platform that targets master regulator brain-body circuits to restore immune homeostasis in autoimmune and inflammatory disease patients.

Ownership category

akta.pro rank

Product category

Immunomodulatory Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Immunomodulatory therapeutics
• Autoimmune disease drugs
• Neural circuit therapeutics
• Inflammatory disease treatments
• Biopharmaceutical drug development

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Drug Development and Commercialization: Pre-revenue biotech company developing novel therapeutics targeting neural circuits. Revenue will be generated through commercializing drugs for autoimmune and inflammatory diseases once preclinical and clinical programs advance through development.

Core offering

Nilo Therapeutics is developing a novel class of medicines based on a Neural Circuit Immunomodulation Platform that targets master regulator brain-body circuits to centrally control systemic inflammation and restore immune homeostasis. The platform is intended to treat a wide spectrum of autoimmune and inflammatory diseases with large unmet medical need through a differentiated mechanism of action distinct from traditional peripheral immunomodulatory therapies. The company is currently in preclinical stage, establishing laboratories in New York City to advance its research programs.

Product overview

Nilo Therapeutics is developing a new class of medicines based on a neural circuit immunomodulation platform that targets master regulator brain-body circuits to centrally control systemic inflammation and restore immune homeostasis. The company is in preclinical stage with programs focused on treating autoimmune and inflammatory diseases. The platform represents a differentiated therapeutic approach compared to traditional immunomodulatory treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• Neural Circuit Immunomodulation Platform A therapeutic platform that targets master regulator brain-body circuits to centrally control systemic inflammation and restore immune homeostasis, intended to treat a wide spectrum of autoimmune and inflammatory diseases through a novel mechanism of action distinct from existing immunomodulatory therapies. The platform is in preclinical stage and is being developed by Nilo Therapeutics in New York City.

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• SetPoint Medical: SetPoint Medical is a clinical-stage company developing bioelectronic vagus nerve stimulation to modulate systemic inflammation in autoimmune diseases (e.g., rheumatoid arthritis, Crohn's). It is the closest direct peer to Nilo, both targeting the neuroimmune axis to restore immune homeostasis in inflammatory disease.
• Galvani Bioelectronics: Galvani Bioelectronics is a GSK/Verily joint venture developing miniaturized, implantable neuromodulation devices to treat chronic diseases including inflammatory and autoimmune conditions. It is a direct peer in neuroimmune modulation via electrical stimulation of disease-relevant neural circuits.
• electroCore: electroCore develops non-invasive vagus nerve stimulation (nVNS) therapies for inflammatory and neurological conditions, including rheumatoid arthritis and other autoimmune indications. It is a direct peer leveraging neural circuit engagement to treat immune-mediated disease.

Broad incumbents

• AbbVie: AbbVie is a global biopharmaceutical leader in immunology (Humira, Skyrizi, Rinvoq) with deep commercial infrastructure in autoimmune and inflammatory disease. It is a broad incumbent whose therapeutic areas fully overlap Nilo's target indications, and an obvious strategic acquirer or partner for any validated neuroimmune asset.
• Sanofi: Sanofi is a major immunology player (Dupixent franchise, growing IL-competitor pipeline) with active interest in differentiated mechanisms for inflammatory disease. As a broad incumbent in autoimmune and inflammatory therapeutics, Sanofi is a directly relevant comparator and potential strategic partner.
• Roche: Roche operates one of the broadest immunology and neuroscience pipelines globally (Ocrevus, Actemra, Vabysmo) and is an obvious benchmark for CNS-immune platform value. As a broad incumbent, Roche is relevant for both competitive and BD comparison purposes.
• Eli Lilly: Eli Lilly is a major immunology and neuroscience incumbent with Taltz, Olumiant, and an expanding neuroimmunology pipeline. As a broad incumbent with deep CNS and inflammation franchises, Lilly is a relevant comparator and potential strategic acquirer.
• Pfizer: Pfizer has a sizeable immunology and inflammation portfolio (Cibinqo, Xeljanz, Litfulo) and an active BD presence in autoimmune disease. As a broad incumbent, it is a directly relevant peer for valuation and partnership benchmarking.

Emerging players

• Karuna Therapeutics: Karuna Therapeutics developed CNS-targeted therapies (xanomeline-trospium) for neuropsychiatric indications and was acquired by Bristol Myers Squibb for ~$14B. It is an emerging peer that demonstrates the premium valuation achievable by CNS-mechanism biotech companies that validate clinically, making it relevant for forward-look upside modeling on Nilo.
• Sage Therapeutics: Sage Therapeutics pioneered CNS-targeted therapeutics (Zurzuvae, Zulresso) and executed a major collaboration with Biogen. As an emerging peer in CNS-mechanism drug development, Sage is relevant for partnership economics and platform valuation comparables.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NILO Therapeutics